The NBA's 65-Game Rule: When a Star's Body Becomes a Variable in Revenue

On February 20, 2026, the San Antonio Spurs issued a statement so brief it felt cold: Victor Wembanyama, the 2.24-metre player in his second NBA season, had been diagnosed with deep vein thrombosis in his right shoulder and would miss the rest of the season. A 21-year-old on the verge of becoming the league's biggest box-office draw was removed from the floor not by a twisted limb in a scramble for the ball, but by a blood clot forming silently in his chest. At the press conference that day, no one talked about tactics. No one talked about the playoffs. There was only a doctor, an anticoagulant protocol, and a schedule still ticking outside the door. To understand why a single medical case pulled an entire debate about league structure along with it, you have to go back two years. In 2026, the NBA signed a new collective bargaining agreement with one of the most contested clauses in decades: to be considered for major awards, including MVP, the All-NBA teams and Defensive Player of the Year, a player must appear in at least 65 of the 82 regular-season games. The clause was designed as a direct remedy for the load-management habit that spread from the late 2010s, when teams began resting stars for entire games to save them for the playoffs. At the same time, the league tightened its Player Participation Policy, barring teams from resting healthy stars in nationally televised games. Behind both moves is money. A game featuring Wembanyama can swing millions of dollars in ticket revenue and hundreds of thousands of viewers. A resting star is a depreciating asset, and the league does not want to pay that bill. But a player's body does not read the labour agreement. It only reads load, recovery time and sleep. From a rehabilitation standpoint, the striking part of Wembanyama's case is not the word thrombosis. It is the word right shoulder. Deep vein thrombosis in the upper limb is rare, and in a young, healthy athlete rarer still. It usually appears when three conditions converge: prolonged obstruction of venous flow, damage to the vessel wall, and blood in a prone-to-clot state. In a 2.24-metre player with an unusually long wingspan, the anatomy around the shoulder and chest creates a venous swirl that most players simply do not have. Add a dense flight schedule between cities, hours seated on planes with a still shoulder, and a repeated volume of shooting, and you have an almost perfect triad. Every injury tells the truth, but it speaks the native language of its system. The system here is a combination of an extraordinary body and a schedule designed for an ordinary one. The schedule itself tells most of the story. An NBA team plays 82 regular-season games, plus up to four NBA Cup games since 2026, plus the play-in tournament if it finishes between seventh and tenth, plus up to four playoff rounds. For a deep run, the total can exceed 100 games in roughly seven months. A team on the West Coast also flies tens of thousands of miles each season, frequently across multiple time zones. To me, someone who has tracked schedules closely and redrawn weekly load charts, the frightening part is not the games themselves but the gaps between them. Research on the acute-to-chronic workload ratio, the ratio between training volume in a given week and the average volume of the preceding weeks, shows injury risk spiking once that ratio passes a certain threshold. The body does not fear hard work. It fears sudden change. A player who steadily plays 35 minutes a night all season may be safer than one who rests for three weeks and is then thrown back in for 38 minutes across four consecutive nights. When the left shoulder compensates for the right, the body has silently rewritten its pain map. At the microscopic level, whenever a joint hurts, the movement chain shifts to a neighbouring joint. A restricted shoulder makes the elbow and wrist carry extra rotational load. A stiff ankle pushes stress onto the knee and hip. These compensations do not hurt immediately. They accumulate in silence, and when they finally erupt, the site of injury is usually not the site of origin. In Wembanyama's case, the compensation chain is more complex because of height. A 2.24-metre body operates at the edge of what the cardiovascular system was designed to do. A long spine, a large rib cage, and a mass of muscle that must pump blood to a greater height than usual. Every sudden change of direction multiplies the force on the ankle, knee and hip in proportion to height. This is why players above 2.15 metres have a far denser history of foot and ankle injuries than the general field. So is the 65-game rule the culprit? This is where things must be separated. The number 65 does not itself create a clot. But it changes how teams manage stars. When individual awards are tied tightly to games played, the pressure to play shifts from the team to the player. A player chasing All-NBA will choose to play a fourth game in four nights rather than rest, even when the body is sending warning signals. A coaching staff, watched by ownership over revenue, gains one more reason not to intervene. The schedule does not kill players; it merely exposes a system weaker than we believed. Here, the weakness lies in screening and load monitoring. Not every NBA team has the staffing to analyse GPS data, monitor sleep and run regular blood tests across the whole roster. Big-market teams do. Small-market teams do not. That gap decides who detects early and who detects late. I once spent weeks reconstructing the load charts of young stars over their first two seasons, based on my experience watching their games and on public data covering minutes, games and travel distance. What I found is that rookies rarely suffer serious injuries in their first season. They break down in their second or third, when the coaching staff has increased their minutes, expanded their role and handed them the offensive burden, without increasing recovery time and medical supervision to match. It is a pattern repeated often enough to be alarming. The irony is that measures meant to protect players can backfire. Resting a star for an entire game to save energy creates a load discontinuity. On return, the body must re-adapt under high intensity. For soft tissue, meaning tendons, ligaments and muscle, that discontinuity is more dangerous than steady play at a controlled volume. Many teams have shifted to a model of reducing minutes without resting games entirely, rather than sitting a player out completely. And here is the counterintuitive point. The problem is not the number of games, but that the league treats 82 games as a uniform product. Players' bodies are not uniform. A 2.24-metre centre, a long-range guard and a defence-first bruiser carry entirely different loads, yet all must obey the same number 65. Recovery is not the shortest road to the finish line, but a map that measures every threshold of tolerance. Any policy that applies one threshold to different bodies is measuring the wrong subject. The signature of a recurrence is not in the twist of the day; it was signed weeks earlier. In Wembanyama's case, the signs may have appeared long before, including an unusually sore shoulder, a mildly swollen arm, a moment of breathlessness under exertion. Those signals are easy to miss in a locker room where everyone is already in some degree of pain. For a young player, this case also raises a question about the future of his contract. Wembanyama is at the start of his rookie deal, and every calculation of long-term value must now add a medical variable. Teams build multi-year plans around stars like him. An event such as deep vein thrombosis, though rare and usually carrying a good prognosis when detected early, forces every plan to recompute its probabilities. This is where medical data enters the negotiating table, not as a side detail but as a central variable. But to read this case only as bad news is to miss the more important part. The Spurs' response, ending the season the moment it was detected and taking no risks, shows a standard that is shifting. A decade ago, a young player might have been encouraged to return once symptoms eased. Today the priority has moved, at least at the teams with the best medical resources. The gap between teams with resources and those without remains, and that is the structural story worth following. What I think will shape next season is not whether Wembanyama returns quickly or slowly. It is whether the NBA dares to look straight at its core contradiction: a league that sells more than 1,200 games a season, while the human body was not designed to play at that density and intensity. Until that question is answered with data rather than slogans, every return season will remain an unwilling experiment, and the bill will keep being sent to the youngest.